Supporting Information

Fan et al. 10.1073/pnas.1216462110

SI Materials and Methods

Antibodies and Reagents. All antibodies were obtained from commercial sources, including anti-YAP, anti-GFP, anti-PDK1, anti-Sav1 (Santa Cruz Biotechnology), anti-phosphoYAP Ser127, anti-Lats1 (Cell Signaling), anti-Mst1/2 (Bethyl Laboratories), anti-human amphiregulin (R&D Systems), α-tubulin, anti-Flag (Sigma-Aldrich), β-actin (GenScript), and GAPDH (Ambion). The following inhibitors were used: PP2, LY294002, AKT inhibitor V, PDK1 inhibitor II, PD98059, U0126 (EMD Biosciences), BX795 (Santa Cruz Biotechnology), Wortmannin, AKT inhibitor VIII, aspirin, Treatment of MCF-10A cells with RNAi experiment for Sav1 knockdown and at different time points for YAP knockdown. For cell proliferation assay, 1×10^6 MCF-10A cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. MCF-10A or MCF-7 cells were transfected using the Amaxa nucleofector system following the manufacturer’s protocol. siRNA were transfected using RNAiMax (Invitrogen) according to the manufacturer’s instruction. Transfected cells were harvested at 72 h after transfection for Sav1 knockdown and at different time points for YAP knockdown. For cell proliferation assay, 1×10^6 MCF-10A cells were seeded for siRNA transfection, and after 12 h, the cell culture medium was changed to basal DMEM/F12 containing EGF only (20 ng/mL). EGF was replenished each day. Cells were collected for cell counts every 24 h for up to 108 h after transfection. Oligonucleotides were synthesized by Dharmaco.

To generate the pEGFP-PDK1 construct, PDK1 cDNA was amplified from MCF-10A cell mRNA and subcloned into the BglII-KpnI site of the pEGFP vector (Clontech). The pEGFP-PDK1-Retr270/473/474LLL construct was generated using the QuickChange site-directed mutagenesis kit (Stratagene). All constructs were confirmed by DNA sequencing. HA-Sav1 and Myc-Mst2 were a kind gift from Dr. Kun-Liang Guan (University of California at San Diego, La Jolla, CA) (2). EGFP-Lats1 and Flag-Lats (Addgene plasmid 19053 and 18971) were a kind gift from Dr. Marius Sudol (Geisinger Clinic, Danville, PA) (3).

Immunoprecipitation and Western Blot Analysis. MCF-10A cells were lysed with hypotonic buffer [10 mM Hepes (pH 7.4), 1 mM EDTA, 150 mM NaCl] supplemented with protease and phosphatase inhibitors. Cell lysates were sheared using a 26G needle and then subjected to low-speed centrifugation (21,130 × g) for 5 min and then high-speed centrifugation (100,000 × g) for 1 h. The resulting supernatants were used for immunoprecipitation. HEK293T cells were lysed with Nonidet P-40 buffer [150 mM NaCl, 1% Nonidet P-40, 50 mM Tris (pH 8.0)] at 24 h after transfection. Cell lysates were incubated with indicated immunoprecipitation antibodies and Sepharose 4 Fast Flow Protein A/G beads (GE Healthcare). The proteins were resolved on SDS-polyacrylamide gels and transferred to a PVDF membrane (Millipore). HRP-conjugated goat anti-mouse or goat anti-rabbit antibodies were purchased from Jackson ImmunoResearch. Western band intensity was measured by ImageJ. Phos-tag SDS/PAGE was used for separation and detection of large phosphoproteins according to published procedures (4, 5).

Chip PCR and RT-PCR. In brief, confluent serum-starved MCF-10A cells were treated with or without EGF for 30 min and crosslinked by 1% formaldehyde. Cell nuclei were lysed and sonicated to generate DNA fragments with an average size of 0.5 kb. Anti-YAP or mouse IgG control antibodies were added to the sonicated chromatin fragments for immunoprecipitation. PCR was performed with Phire Hot Start II DNA polymerase (New England Biolabs). The primer sequences in ChIP were gene promoter amplification were as reported by Zhao et al. (6), with the β-actin gene amplified as an internal control: forward primer, 5′-AACTGGGACGGTGAGGTTG3′; reverse primer, 5′-CTCAAGTGGGGACAAAAA3′. PCR products were confirmed by sequencing.

To assay induction of ChIP mRNA expression, confluent serum-starved MCF-10A cells received control or EGF treatment for 2 h. Total RNA was extracted using the Qiagen RNeasy Kit, followed by cDNA synthesis using SuperScript III Reverse-Transcriptase (Invitrogen). ChIP gene or GAPDH loading control was PCR-amplified by Phusion high-fidelity PCR polymerase (Thermo Scientific). ChIP gene PCR product size was 504 bp (5′ primer, 5′-CTTACCGACTTGGAGACCGT3′; 3′ primer, 5′-ATGCCATGTCTCCGTACACCT3′). 

GAPDH PCR product size was 554 bp (5′ primer, 5′-TGGTTGACCATGAGAAGTT3′; 3′ primer, 5′-TACGTTTGTCATACCGAAAATG3′).

Fig. S1. EGF, serum, and PI3K/PDK1 regulate YAP intracellular localization in various cell types. (A) EGF or serum treatment of confluent serum-starved cells for 30 min induces YAP nuclear accumulation. a–c, A431 cells (epidermoid carcinoma). d–f, HeLa cells (cervical carcinoma). (B) Inhibition of PI3K (Wortmannin 10 μM) or PDK1 (BX795 5 μM) for 2 h induces YAP cytoplasmic retention in tumor cells harboring PI3K mutations. a–c, HCT-116 cells (colorectal tumor). d–f, HT29 cells (colorectal tumor). All of the images were obtained by confocal immunofluorescence microscopy. Nuclear staining with TOPRO3 is shown below each panel. (Scale bar: 20 μm.)

Fig. S2. EGF treatment inhibits Hippo signaling pathway in confluent serum-starved MCF-10A cells. (A) Depletion of YAP by three different siRNAs for the experiment shown in Fig. 1D. The level of YAP expression was determined by Western blot analysis. (B) EGF treatment reduces YAP phosphorylation. MCF-10A cell lysates were resolved on SDS/PAGE gels containing 50 μM phos-tag conjugated acrylamide to separate the various phosphorylated species. Yap polypeptides were detected by Western blot analysis using anti-YAP (Left) or anti-phosphoYAP Ser127 (Right) antibodies.
Fig. S3. EGF treatment inhibits the Hippo pathway through the PI3K-PDK1 pathway, independent of AKT activity. (A) In the same experiment shown in Fig. 2, inhibitor screening of the EGF signaling pathway in MCF-10A cells was done by confocal microscopy of YAP nuclear accumulation. Cells in c–k received a 30-min inhibitor pretreatment, followed by a 30-min EGF treatment. a, no treatment; b, EGF treatment; c, PP2; d, PD98059; e, U0126; f, WP1066; g, G06983; h, Calphostin C; i, FTI-277; j, Rp-CAMPS; k, IP-20. (Scale bar: 20 μm.) (B) Quantification of data shown in A and Fig. 2A. The bar graph shows the percentage of cells with a nuclear, a cytoplasmic, or both a nuclear and cytoplasmic staining pattern. The percentage of cells with nuclear staining was compared in the indicated groups. Statistical significance was calculated using the two-sided Fisher exact test. ***P < 0.0001.
Fig. S4. Dose-dependence of PI3K and PDK1 inhibitors used to inhibit EGF-induced YAP nuclear accumulation. (A) Confluent MCF-10A cells were serum-starved for 24 h, pretreated for 30 min with the indicated inhibitor at the doses shown, followed by a 30-min EGF treatment. a, no treatment; b, 30 min EGF treatment alone; c-f, Wortmannin (PI3K inhibitor); g-i, LY294002 (PI3K inhibitor); j-m, PDK1 inhibitor II; n-q, BX795 (PDK1 inhibitor). YAP localization was determined by confocal microscopy. Nuclear staining with TOPRO3 is shown below each panel. (Scale bar: 20 μm.) (B) Quantification of data shown in A. The bar graph shows the percentage of cells with a nuclear, a cytoplasmic, or both a nuclear and cytoplasmic staining pattern. The percentage of cells with nuclear staining was compared with that in the EGF treatment group. Statistical significance was calculated using the two-sided Fisher exact test. *P < 0.0001.
Fig. S5. Mst-Sav1 binding is not affected by EGF treatment in MCF-10A cells. EGF treatment did not change the binding between Mst and Sav1, as determined by co-IP. Input and co-IP samples were subjected to Western blot analysis with the indicated antibodies. **Antibody heavy chain band.
Fig. S6. PDK1 interacts with Lats1 and Mst through scaffold protein Sav1 in HEK293T cells. (A) Schema of WT Lats1 and Lats1 mutants. Lats contains three domains important for its function in the Hippo pathway: (i) kinase domain, which is critical to phosphorylate YAP; (ii) two PPxY motifs, which mediate Lats interaction with proteins containing the WW domain (e.g., YAP and Sav1); and (iii) a Mob-binding domain. A series of deletion or truncation mutants were made based on these different domains. (B) PPxY motifs of Lats1 are critical for PDK1–Lats1 interaction, as determined by co-IP using exogenous protein expression in HEK293T cells. The bar graph shows the relative binding between Flag-Lats1 and GFP-PDK1. *Nonspecific bands. (C) The Mst2–PDK1 association depends on the Sav1 SARAH domain as determined by co-IP using exogenous protein expression in HEK293T cells. The schematic shows WT Sav1 and Sav1-ΔC280 mutant without the SARAH domain.
Fig. S7. Residues 145–162 of Sav1 mediate Sav1–PDK1 binding in HEK293T cells. (A) Schematic of WT Sav1 and Sav1 mutants. (B) N terminus of Sav1 mediates Sav1–PDK1 binding by co-IP analysis of exogenously expressed proteins in HEK293T cells. The bar graph shows the relative binding of GFP-PDK1 with WT Sav1 and Sav1 mutants. (C) Schematic of Sav1 N-terminal deletion mutants. (D) Residues 145–162 of Sav1 mediate Sav1–PDK1 binding, as determined by co-IP using exogenous protein expression in HEK293T cells. The bar graph shows the relative binding of GFP-PDK1 with different Sav1 N terminus deletion mutants.
Fig. S8. Properties of PDK1-R472/3/4L mutant. (A) Expression of PDK1-R472/3/4L is lower than that of WT PDK1 in MCF-10A cells. GFP-PDK1-wt or GFP-PDK1-R472/3/4L was transfected into MCF-10A cells by electroporation. At 60 h after transfection, MCF-10A cells were collected, and whole-cell lysates were subjected to Western blot analysis with anti-PDK1 antibody. (B) PDK1 PH domain defective mutant binds to Lats1 more abundantly than WT PDK1 in HEK293T cells. Exogenous proteins were coexpressed in HEK293T cells. PDK1 and Lats1 interactions were determined by co-IP and Western blot analysis. The graph quantifies Western blot analysis results. Statistical significance was calculated using the Student t test. The error bar represents mean ± SEM; n = 3.